Drug Profile
Research programme: diabetes therapy - Biovitrum/Medivir
Latest Information Update: 27 Feb 2007
Price :
$50
*
At a glance
- Originator Biovitrum; Medivir AB
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 23 Feb 2007 Discontinued - Preclinical for Type-2 diabetes mellitus in Sweden (unspecified route)
- 21 Jul 2004 Preclinical trials in Type-2 diabetes mellitus in Sweden (unspecified route)